Real-time financial, economic, and global news with market-focused context and analysis.
Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.
Gold advanced modestly in Asian trading after a pullback the previous session, as market participants weighed the effects of newly imposed U.S. import tariffs and awaited a scheduled round of U.S.-Iran discussions. The metal's rise was tempered by expectations of sustained higher U.S. interest rates and a firmer dollar.
Caribou Biosciences NASDAQ:CRBU Chief Technology Officer Timothy P. Kelly reported a February 24, 2026 sale of 3,147 shares at $1.96 per share, yielding $6,168. A Form 4 shows Kelly also acquired 45,000 common shares on February 20, 2026, valued at $0, and obtained options to purchase 202,500 shares at a $1.80 exercise price expiring February 19, 2…
Caribou Biosciences NASDAQ:CRBU Chief Medical Officer Tina M. Albertson sold 1,066 shares on February 24, 2026, for $1.96 per share, totaling $2,089. Earlier in the week she received restricted stock units and option grants. The company also drew a Buy initiation from Clear Street with a $13.00 price target, while InvestingPro flags volatility and …
Ruhi Ahmad Khan, Chief Business Officer at Caribou Biosciences (CRBU), sold 6,938 shares on February 24, 2026, for $1.96 apiece to satisfy tax obligations tied to restricted stock unit vesting. The filings show earlier acquisitions on February 20, 2026 — 45,000 shares at a reported value of $0 and options to buy 202,500 shares at $1.80 that vest mo…
Oil prices remained close to seven-month highs as investors weighed the prospect of supply disruption linked to U.S.-Iran tensions against data showing a large build in U.S. crude stocks. A third round of talks between U.S. envoys and an Iranian delegation is scheduled for Thursday in Geneva, while U.S. naval forces and other military assets remain…
A U.S. magistrate judge has barred federal prosecutors from conducting an unsupervised search of electronic devices seized from a Washington Post reporter in a national security leak investigation, instead ordering a court-supervised review of the material to determine whether the contents contain evidence relevant to the probe. The devices were se…
MOZAYYX Acquisition Corp. priced an initial public offering of 26.1 million units at $10.00 per unit, generating $261 million in proceeds. The units began trading on the New York Stock Exchange on February 25, 2026, under the symbol MZYX.U. Each unit contains one Class A ordinary share and one-quarter of a redeemable warrant; separate trading for t…
Lumine Group (LMGIF) trades near its 52-week low after a sharp derating. The announced Synchronoss acquisition should be accretive to scale and recurring revenue; combined with a crowded short interest profile that is moderating and bullish technical signals, this creates a risk-reward favorable for a contrarian buy at current levels.
The yen slipped toward a two-week low after reports that Prime Minister Sanae Takaichi expressed reservations about further rate increases to the Bank of Japan governor, while a firmer Chinese yuan and a pickup in Australian inflation supported the yuan and Australian dollar. Traders also watched for U.S. signals during the Asia session tied to the…
Ameris Bancorp Chief Financial Officer Nicole S Stokes reported a nominal sale of company stock on February 24, 2026, alongside other equity movements tied to compensation and tax-withholding. The $5.4 billion regional bank also released fourth-quarter 2025 results that slightly beat EPS expectations but missed revenue estimates. Separately, the co…
Benjamin C. Singer, Procore Technologies’ Chief Legal Officer and Secretary, sold 6,938 shares of the company’s common stock between February 23 and February 24, 2026, for roughly $348,023 under a pre-existing 10b5-1 trading arrangement. The stock trades near its 52-week low and had seen a roughly 23% decline over six months. Procore also reported …
Palantir Technologies Chief Accounting Officer Jeffrey Buckley sold 4,646 shares of Class A common stock on February 20 and February 24, 2026, in automated transactions executed under a Rule 10b5-1 plan to satisfy tax withholding tied to vesting restricted stock units. The trades realized roughly $520,000 in proceeds. Palantir shares are trading ma…
Palantir Technologies Inc's CFO and Treasurer, David A. Glazer, disposed of 17,488 shares of Class A common stock on February 20, 2026, in a series of automated transactions to satisfy tax-withholding obligations tied to restricted stock unit vesting. The sales, carried out under a Rule 10b5-1 plan, totaled $2,331,782 based on prices between $132.0…
Palantir Technologies' Chief Technology Officer and Executive Vice President, Sankar Shyam, sold $22.5 million of Class A Common Stock on February 20, 2026, in several transactions. The same day he converted a large block of Class B shares to Class A and received restricted stock units upon vesting. The stock has been under pressure year-to-date, w…
Ryan D. Taylor, an officer at Palantir Technologies Inc (NYSE: PLTR), sold 20,338 Class A shares on February 20, 2026, receiving $2.67 million in proceeds. The disposition was filed on a Form 4 with the SEC and occurred while the stock trades down 27.5% year-to-date and around $128.82 per share. The company has announced a partnership with Rackspac…
UBS analysts have increased their exposure to a basket of Chinese technology companies following a recent selloff in the sector. The bank points to healthy earnings, attractive valuations and expected acceleration in capital expenditure and AI development in 2026 as the drivers for potential returns. UBS adjusted portfolio weightings across large a…
ImmunityBio director Christobel Selecky sold 25,000 shares on February 23, 2026, for $10 apiece, generating $250,000. On the same day she exercised options to buy 25,000 shares at $2.98, a transaction worth $74,500. The sale was carried out under a Rule 10b5-1 plan. The company has reported substantial revenue growth for its cancer therapy ANKTIVA,…
Palantir Technologies CEO Alexander C. Karp sold $65.9 million worth of Class A common stock in a series of transactions on February 20, 2026, and completed several conversions of Class B shares to Class A. The stock is trading below the sales range and is viewed by one service as overvalued versus Fair Value, even as analysts upgraded the shares a…
Palantir Technologies director Stephen Andrew Cohen sold $43.7 million of Class A Common Stock on February 20, 2026 across a series of transactions. The company’s shares have fallen 27.5% year-to-date and trade at a high price-to-earnings multiple. Cohen also converted Class B shares to Class A and restricted stock units were exercised into Class B…
Barry J. Simon, a director at ImmunityBio, sold 175,000 shares of the company’s common stock in late February 2026 for roughly $1.78 million under a pre-arranged Rule 10b5-1 plan. The transactions occurred as the stock traded above its 52-week high amid substantial revenue growth for the company’s cancer therapy ANKTIVA and new distribution deals i…
KalVista Pharmaceuticals CFO Brian Piekos sold 1,767 shares on February 23, 2026, netting $27,506 at a weighted average price of $15.5668 per share. Earlier in the week he exercised options on 5,000 shares and converted 5,000 restricted stock units into common stock. The insider moves come as KalVista reports preliminary fourth-quarter 2025 revenue…
KalVista Pharmaceuticals Chief Medical Officer Paul K. Audhya sold 5,354 shares on February 23, 2026, generating about $83,344. The sale followed the exercise and conversion of 11,250 restricted stock units into common shares on February 21 and 22. KalVista's stock trades around $15.77, and the company reported preliminary global EKTERLY sales of r…
Nicole Sweeny, chief commercial officer of KalVista Pharmaceuticals (KALV), sold 3,975 shares of common stock on February 23, 2026, to satisfy tax-withholding tied to vested RSUs. The sale totaled about $61,878 at a weighted average price of $15.5668. The company reported preliminary fourth-quarter 2025 EKTERLY revenue of roughly $35 million, well …
Fortescue reported a stronger first-half performance driven by a record shipment run and improved realised hematite prices. The miner posted underlying EBITDA of $4.5 billion and net profit after tax of $1.9 billion for the six months to Dec. 31, each up 23% year-on-year, and declared a higher fully franked interim dividend while maintaining full-y…
Christopher Yea, Chief Development Officer at KalVista Pharmaceuticals (KALV), sold 4,347 shares on February 23, 2026, to satisfy tax-withholding obligations stemming from the vesting and settlement of restricted stock units. The transaction was non-discretionary, according to a Form 4 filing. Separately, KalVista reported roughly $35 million in gl…
